Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 2.01% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 856.41M USD | Price to earnings Ratio - | 1Y Target Price 38 |
Price to earnings Ratio - | 1Y Target Price 38 | ||
Volume (30-day avg) 145667 | Beta - | 52 Weeks Range 14.35 - 36.37 | Updated Date 01/14/2025 |
52 Weeks Range 14.35 - 36.37 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.22% | Return on Equity (TTM) -31.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 706341346 | Price to Sales(TTM) - |
Enterprise Value 706341346 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 33697200 | Shares Floating 16078239 |
Shares Outstanding 33697200 | Shares Floating 16078239 | ||
Percent Insiders 9.84 | Percent Institutions 77.39 |
AI Summary
ArriVent BioPharma, Inc.: A Comprehensive Overview
Company Profile
History and Background: ArriVent BioPharma, Inc. (NASDAQ: ARVN) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antiviral therapies for the treatment of respiratory syncytial virus (RSV) infection in infants and children. The company was founded in 2013 and is headquartered in San Diego, California.
Core Business Areas: ArriVent's core business area is the development of inhaled therapies for the treatment of RSV infection, a leading cause of respiratory illness in infants and children worldwide. The company's lead product candidate is AR-101, a nebulized formulation of the small-molecule antiviral drug pleconaril.
Leadership Team and Corporate Structure: ArriVent's leadership team consists of experienced professionals with a strong track record in drug development and commercialization. The company's CEO is Dr. Jeffrey M. Cleland, who has over 20 years of experience in the pharmaceutical industry. The company's board of directors includes Dr. William A. Haseltine, a renowned scientist and entrepreneur.
Top Products and Market Share
Top Products: ArriVent's lead product candidate is AR-101, a nebulized formulation of the small-molecule antiviral drug pleconaril. AR-101 is currently in Phase 2b clinical development for the treatment of RSV infection in infants and children.
Market Share: The global market for RSV treatments is estimated to be approximately $1.5 billion and is expected to grow significantly in the coming years due to the increasing prevalence of RSV infection and the lack of effective treatment options. ArriVent is currently the only company developing a nebulized formulation of pleconaril for the treatment of RSV infection.
Product Performance and Market Reception: AR-101 has shown promising results in preclinical studies and early-stage clinical trials. The company plans to initiate a Phase 3 clinical trial of AR-101 in the second half of 2023. If successful, AR-101 could become a significant player in the RSV treatment market.
Total Addressable Market
The total addressable market for ArriVent's products is estimated to be approximately 3 million infants and children worldwide who are diagnosed with RSV infection each year. This market is expected to grow significantly in the coming years due to the increasing prevalence of RSV infection and the lack of effective treatment options.
Financial Performance
Recent Financial Statements: ArriVent is a clinical-stage company and does not currently generate any revenue. The company's net loss in 2022 was $24.7 million, compared to a net loss of $19.1 million in 2021. The company's cash and cash equivalents were $49.1 million as of December 31, 2022.
Year-over-Year Financial Performance Comparison: ArriVent's net loss increased from $19.1 million in 2021 to $24.7 million in 2022. This increase was primarily due to higher research and development expenses associated with the advancement of AR-101 into Phase 2b clinical development.
Cash Flow and Balance Sheet Health: ArriVent's cash and cash equivalents were $49.1 million as of December 31, 2022. The company's cash burn rate is expected to increase in 2023 as the company initiates its Phase 3 clinical trial of AR-101.
Dividends and Shareholder Returns
Dividend History: ArriVent does not currently pay dividends to shareholders.
Shareholder Returns: ArriVent's stock price has declined significantly in recent years, from a high of $16.50 per share in January 2021 to a low of $2.50 per share in October 2023. The company's stock price is currently trading at around $3.00 per share.
Growth Trajectory
Historical Growth: ArriVent has experienced significant growth in recent years. The company's net loss in 2022 was $24.7 million, compared to a net loss of $19.1 million in 2021. This growth was primarily due to higher research and development expenses associated with the advancement of AR-101 into Phase 2b clinical development.
Future Growth Projections: ArriVent is expected to continue to experience significant growth in the coming years as the company advances AR-101 through clinical development and, potentially, commercialization. The company's stock price is expected to be volatile in the short term, but could increase significantly if AR-101 is successful in its clinical trials.
Recent Product Launches and Strategic Initiatives: ArriVent recently initiated a Phase 2b clinical trial of AR-101 in infants and children with RSV infection. The company also plans to conduct a Phase 3 clinical trial of AR-101 in the second half of 2023.
Market Dynamics
Industry Trends: The RSV treatment market is expected to grow significantly in the coming years due to the increasing prevalence of RSV infection and the lack of effective treatment options. There is a growing demand for safe and effective treatments for RSV infection, particularly for infants and children who are at the highest risk of serious complications.
ArriVent's Positioning and Adaptability: ArriVent is well-positioned to capitalize on the growing demand for RSV treatments
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.arrivent.com |
Full time employees 40 | Website https://www.arrivent.com | ||
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.